Contributors: Virus et Immunité - Virus and immunity (CNRS-UMR3569); Institut Pasteur Paris (IP)-Centre National de la Recherche Scientifique (CNRS); Vaccine Research Institute Créteil, France (VRI); Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12); Université Paris Cité (UPCité); Découverte de pathogènes – Pathogen discovery; Institut Pasteur Paris (IP); Immunologie humorale - Humoral Immunology; Institut Pasteur Paris (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM); Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)); Institut Pasteur Paris (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité); Epidémiologie des Maladies Emergentes - Emerging Diseases Epidemiology; Pasteur-Cnam Risques infectieux et émergents (PACRI); Institut Pasteur Paris (IP)-Conservatoire National des Arts et Métiers CNAM (CNAM)-Institut Pasteur Paris (IP)-Conservatoire National des Arts et Métiers CNAM (CNAM); Département de Virologie - Department of Virology; Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae Paris (CNR - laboratoire coordonnateur); Biologie des ARN et virus influenza - RNA Biology of Influenza Virus; Laboratoire commun Pasteur-TheraVectys; Institut Pasteur Paris (IP)-TheraVectys; Virologie Moléculaire et Vaccinologie / Molecular Virology and Vaccinology; Laboratoire d’innovation : vaccins – Innovation lab : vaccines; Plateforme technologique Production et purification de protéines recombinantes – Production and Purification of Recombinant Proteins Technological Platform (PPR); Virologie Structurale - Structural Virology; Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord; AP-HP - Hôpital Bichat - Claude Bernard Paris; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Investigation Clinique et d’Accès aux Ressources Biologiques (Plate-forme) - Clinical Investigation and Access to BioResources (ICAReB); Coordination du Risque Epidémique et Biologique CHU Necker; Hôpital Necker - Enfants Malades AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Etablissement Français du Sang (EFS); EFS; Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ); CIC Cochin Pasteur (CIC 1417); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité); Santé publique France - French National Public Health Agency Saint-Maurice, France; Centre d'épidémiologie et de santé publique des armées Marseille (CESPA); Service de Santé des Armées; Direction Générale de la Santé (DGS); Ministère de la santé; Conservatoire National des Arts et Métiers CNAM (CNAM); Institut Pasteur Paris (IP)-Conservatoire National des Arts et Métiers CNAM (CNAM); Direction de la recherche médicale de l'Institut Pasteur; École nationale vétérinaire d'Alfort (ENVA); O.S. is funded by Institut Pasteur, ANRS, Sidaction, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), “TIMTAMDEN” ANR-14-CE14-0029, “CHIKV-Viro-Immuno” ANR-14-CE14-0015-01, and the Gilead HIV cure program. L.G. is supported by the French Ministry of Higher Education, Research and Innovation. M.E. is funded by Institut Pasteur, Labex IBEID (ANR-10-LABX-62-IBEID), and REACTing, EU RECOVER, and ANR Oh’ticks grants. H.M. is funded by the Institut Pasteur, the Milieu Intérieur Program (ANR-10-LABX-69-01), INSERM, and REACTing and EU RECOVER grants. C.P. is supported by a fellowship from the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS). S.v.d.W. is funded by Institut Pasteur, CNRS, Université de Paris, Santé publique France, Labex IBEID (ANR-10-LABX-62-IBEID), and REACTing and EU RECOVER grants; ANR-10-LABX-0077,VRI,Initiative for the creation of a Vaccine Research Institute(2010); ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010); ANR-14-CE14-0029,TIMTAMDEN,Rôle des récepteurs TIM et TAM dans l'infection des cellules cibles par le virus de la dengue(2014); ANR-14-CE14-0015,CHIKV-Viro-Immuno,Multiplication et Relation avec l'hôte du virus Chikungunya(2014); ANR-16-CE35-0011,OHTicks,Approche One health pour identifier les agents pathogènes transmis par les tiques et responsables de syndromes inexpliqués chez l'Homme et les animaux(2016); European Project: 101003589, H2020-SC1-PHE-CORONAVIRUS-2020,RECOVER(2020)
نبذة مختصرة : International audience ; It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their differing antibody response profiles. Here, we performed a pilot study of four serological assays to assess the amounts of anti-SARS-CoV-2 antibodies in serum samples obtained from 491 healthy individuals before the SARS-CoV-2 pandemic, 51 individuals hospitalized with COVID-19, 209 suspected cases of COVID-19 with mild symptoms, and 200 healthy blood donors. We used two ELISA assays that recognized the full-length nucleoprotein (N) or trimeric spike (S) protein ectodomain of SARS-CoV-2. In addition, we developed the S-Flow assay that recognized the S protein expressed at the cell surface using flow cytometry, and the luciferase immunoprecipitation system (LIPS) assay that recognized diverse SARS-CoV-2 antigens including the S1 domain and the carboxyl-terminal domain of N by immunoprecipitation. We obtained similar results with the four serological assays. Differences in sensitivity were attributed to the technique and the antigen used. High anti-SARS-CoV-2 antibody titers were associated with neutralization activity, which was assessed using infectious SARS-CoV-2 or lentiviral-S pseudotype virus. In hospitalized patients with COVID-19, seroconversion and virus neutralization occurred between 5 and 14 days after symptom onset, confirming previous studies. Seropositivity was detected in 32% of mildly symptomatic individuals within 15 days of symptom onset and in 3% of healthy blood donors. The four antibody assays that we used enabled a broad evaluation of SARS-CoV-2 seroprevalence and antibody profiling in different subpopulations within one region.
Processing Request
No Comments.